Raf-1 is a cytosolic serine-threonine kinase that plays an important role in tumor cell growth, proliferation, and apoptosis. Upregulated Raf-1 activity has also been implicated in tumor angiogenesis and metastasis. In this study, we used a promising new RNA interfering technology that targets Raf-1 mRNA both in vitro and in vivo. We initially found that Raf-1 siRNA markedly reduced Raf-1 mRNA in MDA-MB-435 cells in vitro by approximately 75% compared to control siRNA treatment groups. Raf-1 siRNA also reduced cell number by inducing apoptosis in a number of cell lines including HUVEC, MDA-MB-435, and C6 cells. After screening several histidine-lysine polymers in complex with Raf-1 siRNA to reduce tumor growth, we further evaluated the efficacy of this siRNA in complex with the optimal histidine-lysine carrier to reduce the tumor growth in vivo. MDA-MB-435 xenografts treated by intratumoral injections of Raf-1 siRNA were significantly reduced compared with the control groups. By the fourth measurement, tumor growth was reduced by nearly 60% in the Raf-1 siRNA treatment group compared with the untreated group (Po.02). Taken together, our data provide evidence that Raf-1 siRNA may be an effective strategy for reducing tumor growth.
R af-1 belongs to a family Raf kinases, each of which binds to Ras and phosphorylates and activates MEK. 1, 2 Recent evidence suggests that Raf isoforms have different physiological functions, perhaps depending on varied cellular milieu or activating different substrates. For example, Raf-1 has been reported to inactivate RB by directly phosphorylating it, thereby enabling cell cycle progression. 3 Alternatively, downregulation of Raf-1 has been reported to activate caspase-3 and apoptosis. 4 From these and other studies, it is evident that Raf-1 plays a central role in diverse cellular functions including proliferation, apoptosis, and differentiation. 5 By affecting similar cellular pathways on solid tumors and hematological malignancies, Raf-1 may be an effective therapeutic target. Targeting Raf-1 with antisense oligonucleotides (ODNs) results in inhibition of tumor growth in vitro and in vivo. Furthermore, when Raf-1 antisense ODN therapy was combined with radiation, there was synergistic reduction in tumor growth in preclinical studies. 6 In addition to Raf-1 directly affecting tumor growth, Raf-1 has a central role in tumor angiogenesis. In endothelial cells, oncogenic Ras or its activated substrate, Raf-1, is associated with increased levels of vascular endothelial growth factor (VEGF), the primary growth factor in inducing tumor angiogenesis. 7 Additionally, Raf-1, by being differentially phosphorylated at separate sites by VEGF or bFGF signal transduction pathways, shields endothelial cells from apoptosis. 8 Finally, Raf-1 has also been demonstrated to affect cancer metastases. 9 Thus, Raf-1 is an attractive therapeutic target since it promotes tumor growth directly, tumor angiogenesis, and formation of metastases.
To take advantage of the importance of Raf-1 in tumor growth and angiogenesis, we explored a new technology, siRNA, that has been used to downregulate markedly the gene of interest. In one report, RNAi silences genes 10-fold more efficiently than antisense RNA alone. 10 To avoid nonspecific gene silencing induced by longer double-stranded RNA, small interfering RNA (siRNA), a duplex of 21-23 nucleotides, has been used as a mediator to degrade target mRNA. 11 Once inside the cell, siRNA is incorporated into an RNA-induced silence complex (RISC), a protein-RNA complex resulting in unwinding and strand separation of the RNA duplex. The antisense RNA then guides the activated RISC to anneal and cleave the target mRNA. [12] [13] [14] [15] Moreover, several in vitro studies have demonstrated that siRNA can effectively reduce tumor oncogenes. tumor cell apoptosis in vitro and in vivo, and to inhibit tumor growth in vivo.
Materials and methods

Cell line
MDA-MB-435 (a human malignant cell line) and C6 cells (a rat glioma) were obtained from the American Type Culture Collection (Manassas, VA) and maintained in Dulbecco's minimal essential medium (DMEM) containing 10% fetal calf serum (FCS) and 20 mM glutamine. Primary human umbilical vein endothelial cells (HUVEC, Cambrex) were grown in EGM-2 Bullet Kit medium (Cambrex).
Polymers and liposomes
The biopolymer core facility at the University of Maryland synthesized polymers on a Ranin Voyager synthesizer (PTI, Tucson, AZ). The branched HK polymer, effective for in vitro siRNA transfer, was as follows: K4b where R ¼ KHHHKHHHKHHHKHHHK. These polymers were selected because of their in vitro or in vivo efficacy for different nucleic acid forms. 21, 22 DOTAP liposomes were prepared as previously described. 23 
siRNA
The Raf-1 siRNA duplex, directed against the sequence 5 0 -AAU GUC CAC AUG GUC AGC ACC-3 0 , was designed to target both human (913-933) and mouse Raf-1 (1089-1109). b-Galactosidase siRNA duplex (234-254) was prepared as a control and directed against the following sequence: 5 0 -AAC UUA AUC GCC UUG CAG CAC-3 0 . The siRNA and biotin labeled Raf-1 siRNA were synthesized by Darmacon (Lafayette, CO).
In vitro experiments
Transfection. Initially, 5 Â 10 4 cells of MDA-MB-435 cells were plated into a 24-well plate containing 500 ml of DMEM and 10% serum. After 24 hours, when the cells were 50% confluent, transfection complexes were added to the media. To prepare complexes at the optimal polymer:siRNA ratio of 4 : 1 (1 or 2 mg of siRNA from a stock solution of 1 mg/ml) in OptiMEM was briefly mixed with the polymer (also from a stock solution of 1 mg/ml) and let stand at room temperature for 30 minutes. The total volume of the polymer/DNA complex in OptiMEM was 50 ml/well. This complex was added directly to a well containing 1 ml of DMEM/10% serum for 48 hours before assessing the efficacy of the Raf-1 siRNA. Similarly, HUVEC and C6 glioma cells were transfected with Raf-1 siRNA (2 mg) in complex with the HK polymer.
In vitro cell survival and apoptosis assays. MDA-MB-435 cells were transfected with Raf-1 siRNA or with the control, b-galactosidase siRNA; 48 hours later, the cells were stained with 0.5% crystal violet in 20% methanol/ phosphate-buffed saline (PBS) for 20 minutes at room temperature. The plate was washed extensively under running tap water and air-dried. Bound crystal violet was dissolved in 0.01 M sodium citrate/50% ethanol/PBS, and optical density values were determined in Spectra MAX250 (Molecular Devices) at 550 nm.
For cellular apoptosis and cell number, the cells were fixed with 100% ethanol for 5 minutes, stained with 50 nM SYTOX green nucleic acid stain (Molecular Probes) for 10 minutes, and the nuclei and their disintegration were observed with a fluorescence microscope.
RT-PCR for human Raf-1 mRNA. The expression of Raf-1 mRNA and b-actin mRNA as an internal standard was investigated by reverse transcriptase-polymerase chain reaction (SuperScripttIII One-Step PT-PCR system kit, Invitrogen, Carlsbad, CA). Total RNA was isolated from treated and untreated MDA-MB-435 cells by using RNAwizt (Ambion, Austin, TX), and RNA integrity was then analyzed by gel electrophoresis. RNA concentration was determined spectrophotometrically in triplicate for each sample. The primers used for RT-PCR of human Raf-1 were 5 0 -TCAGACTTC-TCCACGAA CAC-3 0 (sense) and 5 0 -AACAGACTCTCGCATAC GAT-3 0 (antisense), resulting in a PCR fragment of 368 bp. Primers obtained from the QuantumRNAt bactin Internal Standards kit (Ambion) were used as a control, resulting in a PCR fragment of 294 bp. RT-PCR was performed as follows: cDNA was synthesized at 601C for 30 minutes, followed by denaturation, 941C for 2 minute; for a 30 cycle amplification, the conditions were denaturing, 941C, 15 seconds; annealing, 621C, 30 seconds; extension, 681C, 45 seconds; 30 cycles. The final extension was for 5 minute at 681C. RT-PCR was performed on GeneAmp PCR System2400 (PerkinElmer) and the linearity of the amplified products of Raf-1 and b-actin was verified by analyzing the products at various cycles. RT-PCR products were then subjected to electrophoresis on a 3% agarose gel (2% agarose þ 1% NuSieve GTG Agarose). A Digital image was then taken and analyzed by the Flourchem8800 Imaging system and software (Alpha Innotech Corp, San Leandro, CA).
In vivo experiments
Xenograft experiments. Female adult nude mice (4-6 weeks) were obtained from NCI Frederick. MDA-MB-435 cells (7 Â 10 5 cell/injection) were injected bilaterally into the mammary fat pads of each mouse. After 10 days, when the subcutaneous tumors were established, the mice were separated into six groups to determine the optimal polymer in complex Raf-1 siRNA: (1) K8b:Raf-1 siRNA, and (6) DOTAP liposomes: Raf-1 siRNA. The mice were given two intratumoral injections of polymer-siRNA complex separated by 5 days (12 mg of polymer: 4 mg of siRNA/ tumor/injection). Each group had four mice with eight tumors. Tumor size was assessed with caliper measurements of the tumors in two dimensions 3 days after the second injection and size was calculated by the formula 1/ 2 Â length Â width 2 . In a second MDA-MB-435 xenograft mouse experiment with the optimal HK polymer, we evaluated the following treatment groups: untreated, HK polymer:b-galactosidase siRNA, and the HK polymer: Raf-1 siRNA. The mice were given three intratumoral injections of polymer-siRNA complex. Tumor size was assessed before each injection by caliper measurements of the tumors in two dimensions and 3 days after the last injection.
Immunohistochemical staining. The tumors were fixed with Streck for 48 hours, embedded in paraffin and the tumor sections on glass slides were deparaffinated. Immunocytochemistry for Human Raf-1 was then performed on MDA-MB-435 tumor sections. Endogenous peroxidase activity was blocked by incubating the cells with 3% H 2 O 2 in 100% methanol for 10 minutes, and the sections were then incubated with 3% goat serum for 30 minutes at room temperature. Biotin-labeled anti-Raf-1 polyclonal antibody (Santa Cruz) diluted 1:100 was added to the tumor sections at 41C overnight, and horseradishperoxidase-labeled streptavidan complex (Vector, Burlingame, CA) was then incubated for 30 minutes with the sections. After the chromagen diaminobenzene (DAB) was applied to the tumor sections for 10 minutes, the tumor sections were dehydrated and mounted with glass coverslips.
TUNEL assay. The tumors were first fixed in Streck, embedded in paraffin, and then tissue sections were deparaffinated. The TUNEL assay was carried out in accordance with the manufacturer's instructions of the In situ Cell Death Detection kit (Roche). In brief, after endogenous peroxidase in the tissue section was inhibited with 3% H 2 O 2 , the TUNEL reaction mixture was incubated with the tissue for 60 minutes at 371C in a humidified chamber. After the converter-POD was incubated with tissue sections for 30 minutes at 371C, the DAB substrate was added at room temperature and maintained for 10 minutes. The slides were then mounted with a glass coverslip and examined by light microscopy.
Distribution of injected of biotin-labeled Raf-1 siRNA. To observe the distribution of siRNA within the injected tumor, 4 mg of biotin-labeled Raf-1 siRNA in complex with the polymer was injected intratumorally. After 6 hours, the tumors were removed, fixed with 4% paraformaldehyde, and embedded in paraffin. After deparaffination, the endogenous peroxidase activity was inhibited by incubating the tissue section in 3% H 2 O 2 in 100% methanol for 10 minutes. Thereafter, the slides were washed with PBS and then incubated with 3% goat serum for 30 minutes at room temperature. Horseradishperoxidase-labeled streptavidan complex (Vector) was then added to the tissue sections for 30 minutes after which DAB was applied for 10 minutes. The slides were then dehydrated and mounted with coverslips.
Results
Raf-1 siRNA inhibits growth and induces apoptosis in MDA-MB-435 breast cancer cells
We designed an siRNA targeting mouse and human raf-1, an important mediator of cell growth and apoptosis. To test the ability of siRNA-Raf1 to inhibit a malignant breast cell line, MDA-MB-435, we first determined the effects of this siRNA on cell number. As shown in Figure  1a (Figs 1 and 2) . Induction of apoptosis was illustrated by marked fragmentation or condensation of nuclei in the siRNA-treated group (Fig  2) . By examining five contiguous Â 40 fields, 12.6% of cells were found to be apoptotic in the Raf-1 siRNA group whereas only 1.4 and 1.2% of cells were apoptotic, respectively, in the control carrier and untreated groups (one-way analysis on ranks, P ¼ .008, Raf-1 siRNA vs carrier or untreated). Thus, the siRNA demonstrates significantly greater potency at inhibiting cell number and inducing apoptosis in MDA-MB-435 cells than its controls.
Raf-1 siRNA inhibits Raf-1 mRNA and Raf-1 in vitro
To demonstrate further the biological activity of siRNA on endogenous Raf-1 mRNA, total RNA was purified from MDA-MB-435 cells 24 hours after siRNA transfection. Quantitative RT-PCR and densitometric analyses showed that siRNA Raf-1 reduced Raf-1 mRNA levels by over 70% compared to the group treated with carrier alone (Fig 3) . These findings, which were verified in a second experiment, established the ability of the siRNA to reduce cellular levels of Raf-1 mRNA. Additionally, immunohistochemical staining showed marked reduction of Raf-1 in MDA-MB-435 cells.
Raf-1 siRNA reduced tumor size in vivo
After determining the in vitro efficacy of siRNA Raf-1, we tested the in vivo efficacy of Raf-1 siRNA with intratumoral injections. To determine the most effective polymer for intratumoral delivery of siRNA, we tested the ability of Raf-1 siRNA in complex with one of four histidine-lysine polymers to inhibit tumor growth. These histidine-lysine polymers varied in complexity and/or the relative ratio of histidines and lysines. The most effective K8b . With one of the optimal polymers, H 3 K4b, we further established that the siRNA targeted Raf-1. Similar to the previous in vivo experiment, mice with tumors were first separated into different study groups. Tumors from the Raf-1 siRNA-treated group were significantly reduced compared with those in the untreated group after each injection (Fig 4b) . By the fourth measurement, tumor growth in the Raf-1 siRNA group was reduced by approximately 50 and 60%, respectively, compared with that in the b-gal and untreated groups. The difference in tumor size between the Raf-1 siRNA and control groups was significant (Po.02, Raf-1 siRNA vs untreated; Po.05, Raf-1 siRNA vs b-gal siRNA). Consistent with inhibition of Raf-1 and tumor growth, we observed diffuse distribution of an siRNA within the tumor 6 hours after injection of the polymer carrier in complex with a biotinylated siRNA (Fig 5a, b) . The tumors in the three different study groups were examined by histochemical staining. As expected, siRNA-RAF1 inhibited Raf-1 in vivo compared to the control untreated and b-galactosidase siRNA group (Fig 5c, d) . Notably, siRNA also inhibited C6 gliomas xenografts by nearly 65% when compared to the control untreated group (Po.05; data not shown).
In vivo angiogenesis
To determine whether tumor angiogenesis was inhibited in tumors by the Raf-1 treatments, two mice from both the control and the Raf-1 siRNA groups received an injection of dye via the tail vein. The dye congealed in the blood vessels, and this allowed visualization of the blood vessels in the tumor sections. Quantitative measurement of three Â 100 fields that had the highest blood vessel density per tumor showed that there was obvious reduction in blood vessel density of Raf-1 siRNA-treated tumors compared with that of the b-galactosidase control group (Po.006, t-test , Fig 5e, f) . In the Raf-1-siRNA treated MDA-MB-435 nude mice, there were 1473.7 blood vessels compared with 4273.5 blood vessels in untreated cells, supporting the notion that the mechanism of Raf-1 is at least in part antiangiogenic.
Raf-1 siRNA can induce tumor cell apoptosis
We used TUNEL staining to assess tumor cell apoptosis; as shown in Figure 5g , h, in Raf-1 siRNA group more tumor cells had positive staining. Thus, apoptosis was increased in the Raf-1 siRNA group compared with untreated and b-galactosidase siRNA group. This indicated that retardation of tumor growth was caused by in part by apoptosis. Raf-1 has antiapoptosis functions, 4, 11, 24, 25 and consequently, inhibition of Raf-1 expression can induce apoptosis in the tumor.
Discussion
As Raf-1 has an important role in augmenting tumor angiogenesis and growth, this molecule represents an ideal target for screening new antitumor treatment modalities. As a result, several treatment modalities targeting Raf-1 Figure 2 Raf-1 siRNA increases apoptosis in MDA-MB-435 cells. After transfection with Raf-1 siRNA, cells were washed and stained with SYTOX green. In the Raf-1-siRNA treated group (right), cell numbers were decreased and apoptosis as indicated marked fragmentation (arrows) and nuclear condensation was increased compared to untreated (left) and carrier (middle) control groups. Figure 3 Raf-1 siRNA inhibits Raf-1 mRNA expression. One-step RT-PCR was carried out in control (H 2 O), untreated, b-galactosidase (b-gal) siRNA, and Raf-1 siRNA groups. At 24 hours after transfection, total RNA from each group was extracted, RT-PCR was performed, and the PCR products were analyzed by electrophoresis on a 3% agarose gel. A digital image (Alpha InnoTech Image) was analyzed by FluoChemTM8000 software. b-actin and Raf-1 PCR fragments were, respectively, 294 and 368 bp.
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have been tested for their ability to inhibit tumor growth, including antisense and DNAzyme strategies, kinase inhibitors, and dominant interfering DNA constructs. Some of these agents have entered clinical trials, such as small molecule Raf-1 kinase inhibitor, Bay43-9006, for renal and non-small-cell lung cancers. Although combination therapy with Raf-1 antisense ODNs (in complex with liposomes) together with radiation in a preclinical study inhibited tumor growth with little toxicity, 6 there were with liposomal Raf-1 antisense ODN complexes significant dose-limiting complications, minimal to modest Raf-1 mRNA reductions, and no objective tumor response in a phase 1 clinical trial. 26 Another gene therapy approach showed that a plasmid encoding a dominantnegative Raf-1 resulted in regression of primary and metastatic tumors after one systemic injection in a preclinical study. 27 Nevertheless, plasmid-based therapies contain significant obstacles in that the CpG sequences are immunostimulatory, which may reduce gene expression if they are administered repeatedly. 28, 29 Strategies to reduce the number of CpG sequences in plasmids are now being studied. 30, 31 Although therapeutic delivery of double-stranded RNAi with more than 30 bases readily induces interferon, small inhibitory RNA in most studies between 19 and 21 nucleotide base pairs have not been reported to induce interferon. The sequence-specific effect of siRNA with reduced potential for toxicity has encouraged its widespread use. Nevertheless, there have been few recent reports challenging the viewpoint that siRNA do not induce cytokines. [32] [33] [34] [35] Rossi et al found that siRNA synthesized by T3, T7, or SP6 bacteriophage polymerase strongly induced interferon a and b in a number of cell lines. 33 In contrast, chemically synthesized siRNA did not induce any interferon response in these cell lines. Interferon induction was attributed to the initiating triphosphates on the siRNA resulting from the bacteriophage promoters. In another study, several siRNAs incorporated into lentiviruses or plasmids did induce interferon, 32 but similar to the report of Rossi et al, chemically synthesized siRNA did not. Furthermore, in this study it was noted that when siRNA was incorporated into expression vectors, the H3 RNA polymerase promoter induced less interferon than did the U6 promoter. 32 These reports suggest caution in assuming that siRNA downregulation of its targeted genes is solely sequence-specific. Nevertheless, the vast majority of reports have shown that at least chemically synthesized siRNA do not induce interferon and are sequence-specific in targeting genes. In our study, there was no evidence that siRNA induced interferon since the control siRNA did not affect Raf-1 mRNA levels or the biological phenotypes of the cells studied.
We designed and tested the therapeutic potential of several siRNAs in targeting Raf-1. Although the majority of these siRNAs were without effect, we identified one siRNA that targeted and downregulated Raf-1 mRNA in vitro and markedly reduced blood vessel density and tumor growth in vivo. Nevertheless, we believe that even greater inhibition may be achieved, as outlined below by several strategies to augment further therapeutic efficacy. First, modification of the nucleotide bases of RNAi increases its efficacy and stability. Introduction of various 2 0 -O methyl modifications at selected positions in several siRNAs improved their stability in serum but did not decrease their activity. 36 Although unmodified siRNA was completely degraded within 15 minutes upon exposure to serum, certain 2 0 -O methyl substitutions within siRNA increased its stability with no degradation after 2 hours of serum exposure. After transfection of cells, a 2 0 -O-methyl derivatized siRNA targeting PTEN (phosphatase and tensin homolog) reduced mRNA levels by nearly 70% at 120 hours, whereas the unmodified siRNA had lost most of its efficacy. Thus, we plan to conduct similar experiments to stabilize Raf-1 siRNA. Secondly, since different Raf-1 family members may have varied biological functions with different malignancies in promoting growth and/or inhibition of apoptosis, siRNA directed toward Raf-1 and a second Raf member may be synergistic in reducing tumor growth. We think that BRaf may be such a candidate for siRNA targeting because B-Raf has emerged as the main regulator of the MEK-ERK signal transduction pathway.
1,2 Third, synergism between radiation therapy and antisense strategies has been shown to reduce tumor growth. 6 This radiation therapy may be particularly effective in controlling local tumors such as occur in brain cancer. Although radiation with intratumoral injections is likely to show a synergistic effect, we are also interested in determining whether systemic injections of Raf-1 siRNA with radiation will have a synergistic antitumor effect. Thus far, we expect these overlapping strategies will significantly reduce tumor growth more than the unmodified Raf-1 treatment alone.
In addition to these overlapping strategies, it will be essential to tailor effective carriers for siRNA. We have recently developed highly branched polymers composed of histidine and lysine that are effective carriers of siRNA for experiments in vitro. These highly branched polymers, however, were not particularly effective as carriers of Raf-1 for intratumoral delivery. For intratumoral injections of Raf-1 siRNA, the two four-branched HK polymers with a lower lysine content (e.g. H 2 K4b, H 3 K4b) were the most effective carriers. For intratumoral delivery of plasmids, the optimal polymer was the four-branched polymer with the lowest lysine:histidine ratio (H 3 K4b); this polymer was significantly better as a carrier of plasmids compared to H 2 K4b and other HK polymers (data not shown). These results, in general, suggest that carriers with a higher positive charge hinder the delivery/and or expression of nucleic acids when injected intratumorally. We wish to extend these intratumoral experiments to orthotopic brain tumor models. Finally, future studies are planned to determine if the general principles for intratumoral HK carrier development apply to intravenous delivery of siRNA.
